Loading...
OTCM
HYPMY
Market cap2.77bUSD
Jul 09, Last price  
3.96USD
1D
0.00%
1Q
-15.73%
Jan 2017
-49.87%
IPO
-70.74%
Name

Hypera SA

Chart & Performance

D1W1MN
OTCM:HYPMY chart
P/E
11.93
P/S
1.85
EPS
1.70
Div Yield, %
1.24%
Shrs. gr., 5y
0.15%
Rev. gr., 5y
13.49%
Revenues
7.70b
+3.45%
380,267,0001,061,500,0001,332,994,0001,966,637,0002,792,301,0003,324,630,0003,873,683,0004,258,740,0002,768,096,0002,956,649,0003,228,092,0003,499,899,0003,724,309,0003,294,749,0004,088,871,0005,937,373,0007,546,355,0007,914,658,0007,442,466,0007,699,157,000
Net income
1.20b
-10.86%
-2,932,00042,100,000-207,876,000292,106,000261,901,000-54,651,000203,913,000256,722,000402,695,000559,872,0001,177,748,000964,942,0001,129,601,0001,164,040,0001,295,116,0001,330,208,0001,696,697,0001,647,960,0001,340,990,0001,195,369,000
CFO
1.43b
-43.76%
-16,107,000143,969,00086,645,000193,504,00067,236,000580,234,000713,805,000665,784,000664,000,000323,692,000881,756,000932,612,0001,066,494,000823,882,0001,183,054,0001,399,131,0002,038,793,0002,395,993,0002,539,599,0001,428,358,000
Dividend
Oct 04, 20240.023285 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical enterprise. The company's comprehensive product line encompasses a wide array of prescription medications, featuring established brands such as Adacne, Celestamine, Cizax, Diprosone, and Emprol XR, among many others. Beyond prescription drugs, Hypera offers specialized dermo-cosmetics through its Mantecorp Skincare brand. Its consumer health division markets popular remedies like Apracur, Benegrip, Engov, and Estomazil. Additionally, Hypera provides nutritional and vitamin supplements, including well-known names such as Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal. The company also maintains a significant presence in the generic and similar medicines market, offering products under the Neo Química brand and common formulations like Ibuprofen, Paracetamol, and Omeprazole. The organization officially became Hypera S.A. in February 2018, having previously operated as Hypermarcas S.A.
IPO date
Apr 16, 2008
Employees
9,000
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT